Personalized medicine CerFlux focuses on matching treatments to tumors through personalized medicine technology, presenting a sales opportunity to biotech and pharma customers seeking precision oncology solutions and faster, cost-effective treatment matching.

Strategic partnerships Past collaborations with Azure Biosystems and grant funding signals openness to partnerships and co-development, suggesting potential alliance opportunities with instrument, diagnostic, or service teams to broaden capabilities and clinical validation.

Small but growing With a lean team and revenue in the low millions, CerFlux may benefit from additional pilot programs, contract R&D work, and grant-supported projects to scale capabilities without large upfront commitments.

Industry engagement Active participation in industry events like Fierce Biotech Week indicates a willingness to engage with policymakers and thought leaders, creating openings for advisory roles, speaking engagements, or sponsored roundtables to raise visibility.

Funding runway Current funding of a few hundred thousand alongside modest revenue suggests a need for revenue-generating pilots, grant-ready proposals, and strategic customers to validate the platform in real-world settings and attract larger investment.